exatecan
Small molecule targets TOP1 via inhibition
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00045318 | May 2002 → Oct 2007 | cancer of unknown primary site | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00004212 | Sep 1999 → Apr 2004 | central nervous system neoplasm, childhood malignant neoplasm, lymphoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT00004047 | Jun 1999 → Apr 2005 | leukemia, myelodysplastic syndrome | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT00055939 | Jan 2003 → Apr 2006 | sarcoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00055952 | Jan 2003 → Apr 2006 | sarcoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00041236 | May 2002 → Dec 2004 | sarcoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT00017212 | Apr 2001 → Sep 2003 | esophageal cancer, gastric cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00005938 | Mar 2000 → Apr 2005 | extrahepatic bile duct carcinoma, gallbladder cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00004866 | Jan 2000 → Sep 2003 | cervical cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00004108 | Sep 1999 → Apr 2005 | liver cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00004060 | Jul 1999 → Sep 2000 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00004046 | Jun 1999 → Apr 2002 | breast cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00004045 | Jun 1999 → Aug 2001 | prostate cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00003951 | Jun 1999 → Apr 2005 | malignant pancreatic neoplasm | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00005091 | Feb 1999 → Aug 2003 | lung cancer | Daiichi Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00023972 | Jul 2001 → Apr 2005 | malignant pancreatic neoplasm | Daiichi Sankyo | Completed | Missed primary |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | exatecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004046 ↗ |
| Known as | DX-8951 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1614650 ↗ |
| Known as | DX-8951f | “Exatecan (DX-8951f) is a totally synthetic analogue of the topoisomerase I-inhibitor camptothecin, which was synthesised to impart increased aqueous solubility, greater tumour...” PMID 17336054 ↗ Mar 20076“Determine the maximum tolerated dose of exatecan mesylate (DX-8951f) with and without filgrastim (G-CSF) in pediatric patients with advanced solid tumors or lymphomas.” NCT00004212 ↗ “Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.” PMID 12114413 ↗ Jul 2002 “Arm I: Patients receive exatecan mesylate (DX-8951f) IV over 30 minutes immediately followed by gemcitabine IV over 30 minutes on days 1 and 8.” NCT00023972 ↗ “Exatecan mesylate (DX-8951f) is a water soluble analogue of camptothecin that inhibits topoisomerase I.” PMID 12871785 ↗ Aug 2003 “Patients receive exatecan mesylate (DX-8951f) IV over 30 minutes on days 1-5.” NCT00017212 ↗ “Patients receive DX-8951f IV over 30 minutes daily for 5 days.” NCT00004046 ↗ |
| Known as | Exatecan mesilate dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1614650 ↗ |
| Known as | Exatecan mesilate hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1614650 ↗ |
| Known as | exatecan mesylate | “Determine the maximum tolerated dose of exatecan mesylate (DX-8951f) with and without filgrastim (G-CSF) in pediatric patients with advanced solid tumors or lymphomas.” NCT00004212 ↗5“Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.” PMID 12114413 ↗ Jul 2002 “PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have advanced soft tissue sarcoma.” NCT00041236 ↗ “Exatecan mesylate is a hexacyclic, water-soluble, topoisomerase-1 inhibitor.” PMID 16983112 ↗ Sep 2006 |
| Known as | Exatecan methanesulfonate dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1614650 ↗ |
| Action | Inhibit | “DNA topoisomerase I inhibitor” CHEMBL1614650 ↗1“topoisomerase I inhibitor” PMID 12114413 ↗ Jul 2002 |
| Modality | Small molecule | “DX-8951f is a novel hexacyclic camptothecin-analogue topoisomerase I inhibitor” PMID 12114413 ↗ Jul 2002 |
| Route | Intravenous | “Patients receive DX-8951f IV over 30 minutes daily for 5 days.” NCT00004046 ↗ |
| Target | TOP1 | “DNA topoisomerase I inhibitor” CHEMBL1614650 ↗ |